Mirtazapine enantiomers in blood and cerebrospinal fluid

Neuropsychobiology

Volumn 54, Issue 3, 2007, Pages 179-181

  Baumann, Pierre ^a,c   Jonzier Perey, Michèle ^a   Paus, Erik ^a   Nikisch, Georg ^b  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^b KLINIKUM FULDA   (Germany)

^c Hopital de Cery   (Switzerland)

Author keywords

Depressive patients; Mirtazapine enantiomers

Indexed keywords

8 HYDROXY MIRTAZAPINE; DRUG METABOLITE; MIRTAZAPINE; N DEMETHYLMIRTAZAPINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; DEPRESSION; DRUG BLOOD LEVEL; DRUG TRANSPORT; HUMAN; MALE; PRIORITY JOURNAL; STEREOCHEMISTRY;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DEPRESSIVE DISORDER; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIANSERIN; SEVERITY OF ILLNESS INDEX; STEREOISOMERISM;

EID: 33847765815     PISSN: 0302282X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000098654     Document Type: Article

References (15)

1. Baumann P, Hiemke C, Ulrich S, Eckermann G, Gaertner I, Kuss HJ, Laux G, Müller-Oerlinghausen B, Rao ML, Riederer P, Zernig G: The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry. Pharmacopsychiatry 2004;37:243-265.
2. de Lange EC, Danhof M: Considerations in the use of cerebrospinal fluid pharmacokinetics to predict brain target concentrations in the clinical setting - Implications of the barriers between blood and brain. Clin Pharmacokinet 2002;41:691-703.
3. Haddjeri N, Blier P, De Montigny C: Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine. Int Clin Psychopharmacol 1995;10(suppl 4):11-17.
4. 2- adrenoceptor antagonist mirtazapine on the 5-hydroxytryptamine system in the rat brain. J Pharmacol Exp Ther 1996;277:861-871.
5. McGrath C, Burrows GD, Norman TR: Neurochemical effects of the enantiomers of mirtazapine in normal rats. Eur J Pharmacol 1998;356:121-126.
6. Paus E, Jonzier-Perey M, Cochard N, Eap CB, Baumann P: Chirality in the new generation of antidepressants: stereoselective analysis of the enantiomers of mirtazapine, N-demethylmirtazapine and 8-hydroxymirtazapine by LC-MS. Ther Drug Monit 2004;26:366-374.
7. Timmer CJ, Sitsen JMA, Delbressine LP: Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000;38:461-474.
8. Delbressine LPC, Moonen MEG, Kaspersen FM, Wagenaars GN, Jacobs PL, Timmer CJ, Paanakker JE, Vanhal HJM, Voortman G: Pharmacokinetics and biotransformation of mirtazapine in human volunteers. Clin Drug Invest 1998;15:45-55.
9. Nikisch G, Agren H, Eap CB, Czernik A, Baumann P, Mathé AA: Neuropeptide Y and corticotropin-releasing hormone in CSF mark response to antidepressive treatment with citalopram. Int J Neuropsychopharmacol 2005;8:403-410.
10. Nikisch G, Mathé AA, Czernik A, Eap CB, Jimenez-Vasquez P, Brawand-Amey M, Baumann P: Stereoselective metabolism of citalopram in plasma and cerebrospinal fluid of depressive patients - Relationship with 5-HIAA in CSF and clinical response. J Clin Psychopharmacol 2004;24:283-290.
11. Dodd S, Burrows GD, Norman TR: Chiral determination of mirtazapine in human blood plasma by high-performance liquid chromatography. J Chromatogr B 2000;748:439-443.
12. Marzolini C, Paus E, Buclin T, Kim RB: Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13-33.
13. Uhr M, Grauer MT, Holsboer F:. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol Psychiatry 2003;54:840-846.
14. Bertilsson L, Otani K, Dahl ML, Nordin C, Åberg-Wistedt A: Stereoselective efflux of (E)-10-hydroxynortriptyline enantiomers from the cerebrospinal fluid of depressed patients. Pharmacol Toxicol 1991;68:100-103.
15. Nordin C, Bertilsson L: Active hydroxymetabolites of antidepressants: emphasis on E-10-hydroxy-nortriptyline. Clin Pharmacokinet 1995;28: 26-40.